| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.27 | 3e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.16 | 8e-06 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-05 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.3 | 4e-05 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.14 | 8e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.19 | 8e-05 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.0001 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |